Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2005

View Archived Issues

S-23521, a novel GLP-1 analogue, prevents progression of diet-induced diabetes in an animal model

Clinical evidence supports the use of oral paricalcitol in SHPT

NXY-059 in acute ischemic stroke: first results of the SAINT I study

Enrollment completed in dose dense Abraxane study in adjuvant breast cancer

Conforma's Series C financing to fund development of Hsp90 inhibitors

Sorafenib accepted into Pilot 1 Program

Noxxon Pharma demonstrates in vivo efficacy of Spiegelmers in cancer

VioQuest to acquire Greenwich Therapeutics

Acorda reaches SPA agreement on Fampridine-SR phase III study in MS

Genentech IND cleared for phase I trial in basal cell carcinoma

BioMarin licenses further 6R-BH4 rights from Daiichi Suntory

Orphan drug designation for arimoclomol for ALS

SB-509 enters new phase I trial for diabetic neuropathy

Novel IGF-IR inhibitor synthesized

Milestones in Rigel and Daiichi collaboration

Cytochroma secures financing

Novel analgesic agents imparted by Neurogen, Euroceltique and Merz

Strong anticancer activity of novel MetAP2 inhibitors

Full enrollment reached in phase III ACCLAIM chronic heart failure trial

TL-310: a possible clinical candidate for cancer / News in Context

Novel agents for arthritis and other inflammatory disorders

Encouraging results with twice-daily avanafil

Schering-Plough discloses new therapeutic agents for erectile dysfunction

GSK discloses novel agents for renal and cardiovascular disorders and cancer

Rostaporfin prevents visual loss in wet AMD patients with occult CNV lesions

Update on the efficacy of ezetimibe plus statin therapy in hypercholesterolemia

Ornidazole prevents postoperative Crohn's disease recurrence

Telmisartan safe, effective in chronic kidney disease patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...